Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
In: Medical Letter on the CDC & FDA, 2023-11-03, S. 876-876
serialPeriodical
Zugriff:
Keywords: Adverse Drug Reactions; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Biopsies; Biopsy; Cancer; Clinical Research; Clinical Trials and Studies; Contraception; Contraceptives; DNA Viruses; DNA Viruses - Hepatitis B Virus; Drugs and Therapies; FDA; Genetics; Government Agencies Offices and Entities; Health and Medicine; Hepadnaviridae; Hepatitis B Virus; Hysterectomy; Imatinib Therapy; Liver Diseases and Conditions; Microbiological Techniques; Oncology; Operative Surgical Procedures; Orthohepadnavirus; Pharmaceuticals; Protein Kinase Inhibitors; Reproductive Medicine; Reproductive Techniques; Risk and Prevention; Surgery; Tyrosine Kinase Inhibitors; U.S. Food and Drug Administration; Viral; Viral Load; Virology; Virus; Virus Physiological Phenomena; Women's Health EN Adverse Drug Reactions Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Biopsies Biopsy Cancer Clinical Research Clinical Trials and Studies Contraception Contraceptives DNA Viruses DNA Viruses - Hepatitis B Virus Drugs and Therapies FDA Genetics Government Agencies Offices and Entities Health and Medicine Hepadnaviridae Hepatitis B Virus Hysterectomy Imatinib Therapy Liver Diseases and Conditions Microbiological Techniques Oncology Operative Surgical Procedures Orthohepadnavirus Pharmaceuticals Protein Kinase Inhibitors Reproductive Medicine Reproductive Techniques Risk and Prevention Surgery Tyrosine Kinase Inhibitors U.S. Food and Drug Administration Viral Viral Load Virology Virus Virus Physiological Phenomena Women's Health 876 876 1 10/30/23 20231103 NES 231103 2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Staff editors report on the newly launched clinical trial, NCT06087263, which has the following summary description: "To learn if regorafenib can help to control the disease.". [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2023-11-03, S. 876-876 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Sonstiges: |
|